ICON Announces Appointment of Professor William Hall to Board of Directors
21 Février 2013 - 6:30PM
Business Wire
ICON plc, (NASDAQ: ICLR), a global provider
of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Professor William Hall as a non-executive
director.
A renowned expert in infectious diseases and virology, Professor
Hall is Chair of Medical Microbiology and Director of the Centre
for Research in Infectious Diseases at University College Dublin’s
(UCD) School of Medicine and Medical Science. He is also a director
of UCD’s National Virus Reference Laboratory and is a consultant
microbiologist at St. Vincent’s University Hospital Dublin.
Professor Hall also serves as a consultant to the Minister of Heath
and Children in the Republic of Ireland, providing input on a
number of topics including influenza pandemic preparedness and
bioterrorism.
Prior to his tenure at UCD, Professor Hall was Professor and
Head of the Laboratory of Medical Virology, Senior Physician and
Director of the Clinical Research Centre at the Rockefeller
University in New York. He has also served as an Assistant and
Associate Professor of Medicine at Cornell University.
Professor Hall is a board member of The Atlantic Philanthropies
and is a co-founder of the Global Virus Network.
“We are delighted to welcome Professor Hall to the ICON Board,”
commented Chairman, Mr. Thomas Lynch. “His knowledge and expertise
in virology and infectious diseases, coupled with his international
research collaborations in these fields will complement the
strengths and talents of our existing board members.”
The information contained in this release is as of 21st February
2013. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to
ICON and its business can be found in ICON’s Annual Report for the
fiscal year ended December 31, 2011 and in the forms filed with the
US Securities and Exchange Commission, including the Forms 20-F,
F-1, S-8 and F-3. ICON disclaims any intent or obligation to update
these forward-looking statements.
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 79
locations in 37 countries and has approximately 10,045 employees.
Further information is available at www.iconplc.com.
Source: ICON plc
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024